We have built a differentiated pipeline of novel drug targets... The Series B accelerates our pipeline expansion, particularly for our bispecific program, TRIV-573, which uniquely combines two orthogonal mechanisms of action. This approach has the potential to significantly enhance therapeutic efficacy.
This fresh capital will be used to accelerate the development of Triveni Bio's innovative pipeline, which is focused on antibody-based therapies for I&I disorders, an area with significant unmet medical need.
The company's flagship bispecific program, TRIV-573, has garnered attention for its unique dual mechanism of action, which holds promise for improving treatment outcomes in conditions where standard therapies fall short.
Triveni's TRIV-573 combines inhibition of kallikreins 5 and 7 (KLK 5/7) with an IL-13 mechanism, offering a powerful combination to tackle difficult-to-treat conditions.
Collection
[
|
...
]